Zerlasiran (SLN360) is a siRNA targeting apolipoprotein A (ApoA). Zerlasiran targets hepatic ApoA synthesis via RNA interference to degrade encoding mRNA. Zerlasiran can be used for the research of atherosclerotic cardiovascular disease and elevated ApoA levels[1][2].
Molecular Weight:
14155.81
Purity:
95.52
CAS Number:
[2646703-64-0]
Formula:
C443H594F12N144O277P40S10
Target:
Apolipoprotein,Small Interfering RNA (siRNA)
Application Notes:
MCE Product type: Oligonucleotides
* VAT and and shipping costs not included. Errors and price changes excepted
